Brief: Transcode Therapeutics Inc Says On May 16, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
18/05/2023 14:30
May 18 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS INC - ON MAY 16, CO RECEIVED NOTICE
OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Source text for Eikon: ID:
Further company coverage: RNAZ.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors